It feels weird to be covering the WCLC from Singapore remotely after remembering the rain in Spain at WCLC19!

If we look at the more mature phase 2 data now available for Amgen’s sotorasib (AMG 510) in KRAS G12C driven lung cancers, we learn there are quite a few nuances and subtleties at play. These aren’t always obvious in top line press releases or even in presentations until we consider the broader niche in which they are competing.

Amgen submitted the sotorasib applications to both the US and EMA health authorities in December.  With breakthrough designation status and clinical evidence of activity in an area of high unmet medical need, it’s hard to believe the approval won’t be forthcoming sooner rather than later, at least in the US.

Mirati is expected to showcase their phase 2 data later this year, so I would highly encourage people to hold off with cross-trial comparisons until we see how their more robust data look at the RP2D.

In the meantime, we can take a careful look at the latest Amgen data.  We do those not only from a BSB review but also through the lens of a company perspective and consider some of the key strategic issues we need to start thinking about…

To learn more about the WCLC20 data and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by